Recombinant protein corresponding to human VEGF expressed in E. coli.
The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells. Applications: Suitable for use in ELISA and Western Blot. Other applications have not been tested. Recommended Dilutions: ELISA (Sandwich): 0.25-1ug/ml using (100ul/well antibody solution) In conjunction with anti human VEGF (V2110-09A) as a capture antibody, allows the detection of at least 0.2-0.4ng/well of recombinant human VEGF165. Western Blot: 0.1-0.2ug/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant human VEGF is 1.5-3ng/lane, under either reducing or non-reducing conditions. Optimal working dilutions to be determined by researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20C. Reconstitute with sterile PBS, 0.1% BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Supplied as a lyophilized powder from PBS, pH 7.2. No preservative added.. Reconstitute with sterile PBS, 0.1% BSA to a concentration of 0.1-1mg/ml. Do not vortex. Labeled with Biotin.
* VAT and and shipping costs not included. Errors and price changes excepted
